APC and cancer: Bisleuconothine A suppressed Wnt/β-catenin signaling by inhibition of nuclear translocation of β-catenin via a mechanism dependent of β-catenin phosphorylation and independent of APC. Taken together, our study suggested that Bisleuconothine A might be developed into therapeutic agents against various cancers bearing aberrant upregulation of Wnt signaling.